Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Acquired Resistance to Antibody-Drug Conjugates.

Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G.

Cancers (Basel). 2019 Mar 20;11(3). pii: E394. doi: 10.3390/cancers11030394. Review.

2.

Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.

Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N, Elschenbroich S, Klammer M, Blackler A, Liao WL, Tian Y, Friess T, Bossenmaier B, Dietmann G, Schaab C, Hembrough T, Ceppi M.

PLoS One. 2019 Mar 21;14(3):e0213892. doi: 10.1371/journal.pone.0213892. eCollection 2019.

3.

Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.

Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, Bossenmaier B, Niederfellner G, Tai CH, Reiter Y, Pastan I.

Cancer Immunol Res. 2017 Aug;5(8):685-694. doi: 10.1158/2326-6066.CIR-16-0330. Epub 2017 Jul 3.

4.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

5.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.

PLoS One. 2017 May 11;12(5):e0177331. doi: 10.1371/journal.pone.0177331. eCollection 2017.

6.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

7.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN.

Clin Cancer Res. 2016 Feb 15;22(4):877-85. doi: 10.1158/1078-0432.CCR-15-1683. Epub 2015 Oct 13.

8.

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.

Meneses-Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, Thomas M, Bossenmaier B.

Cancer Chemother Pharmacol. 2015 Apr;75(4):837-50. doi: 10.1007/s00280-015-2697-8. Epub 2015 Feb 22.

9.

Deciphering the stepwise binding mode of HRG1β to HER3 by surface plasmon resonance and interaction map.

Peess C, von Proff L, Goller S, Andersson K, Gerg M, Malmqvist M, Bossenmaier B, Schräml M.

PLoS One. 2015 Feb 6;10(2):e0116870. doi: 10.1371/journal.pone.0116870. eCollection 2015.

10.

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.

Terwisscha van Scheltinga AG, Lub-de Hooge MN, Abiraj K, Schröder CP, Pot L, Bossenmaier B, Thomas M, Hölzlwimmer G, Friess T, Kosterink JG, de Vries EG.

MAbs. 2014 Jul-Aug;6(4):1051-8. doi: 10.4161/mabs.29097. Epub 2014 May 7.

11.

Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation.

van Dieck J, Schmid V, Heindl D, Dziadek S, Schraeml M, Gerg M, Massoner P, Engel AM, Tiefenthaler G, Vural S, Stritt S, Tetzlaff F, Soukupova M, Kopetzki E, Bossenmaier B, Thomas M, Klein C, Mertens A, Heller A, Tacke M.

Chem Biol. 2014 Mar 20;21(3):357-68. doi: 10.1016/j.chembiol.2013.12.018. Epub 2014 Feb 13.

12.

Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.

Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Harring SV, Bauss F, Burtscher H, Lammers R, Bossenmaier B.

Mol Oncol. 2013 Dec;7(6):1142-51. doi: 10.1016/j.molonc.2013.08.009. Epub 2013 Sep 3.

13.

RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.

Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, Hopfner KP, Niederfellner G, Bossenmaier B.

Cancer Res. 2013 Aug 15;73(16):5183-94. doi: 10.1158/0008-5472.CAN-13-0099. Epub 2013 Jun 18.

14.

Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.

Kollmorgen G, Bossenmaier B, Niederfellner G, Häring HU, Lammers R.

PLoS One. 2012;7(12):e53050. doi: 10.1371/journal.pone.0053050. Epub 2012 Dec 31.

15.

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.

Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.

16.

Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.

Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, Bossenmaier B, Umana P, Sustmann C, Brinkmann U.

Protein Eng Des Sel. 2012 Oct;25(10):571-80. Epub 2012 Sep 13.

17.

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.

Cancer Res. 2009 Dec 15;69(24):9330-6. doi: 10.1158/0008-5472.CAN-08-4597.

18.

The 1.1 A resolution crystal structure of the p130cas SH3 domain and ramifications for ligand selectivity.

Wisniewska M, Bossenmaier B, Georges G, Hesse F, Dangl M, Künkele KP, Ioannidis I, Huber R, Engh RA.

J Mol Biol. 2005 Apr 15;347(5):1005-14.

PMID:
15784259

Supplemental Content

Loading ...
Support Center